No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial
|Date||April 14, 2020|
Non-randomized trial of 181 COVID-19 patients hospitalized for hypoxic pneumonia treated with hydroxychloroquine or standard therapy with primary endpoint of transfer to ICU. Of the patients treated with hydroxychloroquine, 20% also received azithromycin. There was no difference between treatment groups in transfer to ICU or death 7 days after hospital admission.
Based on C-reactive protein levels, most patients were already in a cytokine storm by the time treatment was initiated, which supported the theory that hydroxychloroquine is unlikely to be effective once patients are in a cytokine storm.
No major issues identified at this time.
No minor issues identified at this time.
This study supported evidence that hydroxychloroquine has minimum to non-existent effects in late stage disease where patients are in cytokine storm.
None at this time.